Diagnosis and treatment of diffuse large B cell lymphoma in children and adults (review of literature)

Diffuse large B-cell lymphoma (DLBCL) includes heterogeneous disease variants according to clinical, morphological, immunological, cytogenetic and molecular-biological features. Several different pediatric and adult protocols are presented in this article (AIEOP NHL92, B-NHL-BFM90, POG APO - IDM/HiDAC, B-NHL-BFM95, FAB/LMB96, BNHL03, FAB/LMB96 + rituximab, B-NHL2004m + rituximab, R-CHOP, DA-EPOCH-R, RB-CHOP, RBV-CHOP). There were revealed some factors of unfavorable outcome of disease in adult patients with DLBCL, that allow to improve risk group stratification and reduce chemotherapy intensiveness in some patients but require additional study in pediatric patients at the present time. Particular attention is paid to study of sensitiveness to target therapy (anti-CD20 monoclonal antibodies).